They had suffered a heart attack or unstable angina. They were randomly assigned to clopidogrel or prasugrel. The results showed that not increase the use of PPI in combination with these drugs, the risk of cardiovascular events, including death, heart attack or stroke. – The authors write in conclusion: ‘These results do not support the need to avoid concomitant use of proton pump inhibitors, when clinically indicated, in patients receiving clopidogrel or prasugrel. ‘.. As part of a strategy that has been approved by the current guidelines , PPIs are often to help with clopidogrel and prasugrel, the risk of gastrointestinal bleeding are administered.
About the EMPOWER studythe EMPOWER study, a randomized, double-blind, placebo-controlled study is conducted to evaluate the safety and effectiveness of the company’s investigational VBLOC evaluating treatment after 12 months of use in obese patients, the study will be performed on. Up to 15 sites in the U.S. And Australia and will include up to 300 patients with obesity. The company expects high frequencythe first half of 2008 to complete. Qualify for the study qualify for the study, patients must be 18 years or older. With a body mass index between 35 and 45 years To learn more about the EMPOWER study, visit.The investigators found that nicotine chemotherapeutics, have as gemcitabine, cisplatin and taxol, stop of destruction of lung cancer cells of. The finding was reports at the annual session which American Association for Cancer Research.